Current Liabilities
Accounts Payable
Edwards Lifesciences Accounts Payable decreased by 20.4% to $181.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.0%, from $172.40M to $181.10M. Over 5 years (FY 2020 to FY 2025), Accounts Payable shows an upward trend with a 3.0% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026
How to read this metric
An increase can indicate better credit terms or increased production volume, while a decrease might suggest faster payments or reduced purchasing.
Detailed definition
The amount of money a company owes to its suppliers and vendors for goods and services purchased on credit. In a large-s...
Peer comparison
Companies with significant supply chain leverage often maintain high payables to maximize their own cash-on-hand.
Metric ID:
accounts_payableHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $144.60M | $139.50M | $204.50M | $158.80M | $162.50M | $154.90M | $201.90M | $180.80M | $193.00M | $190.60M | $201.40M | $212.30M | $185.90M | $172.80M | $197.40M | $172.40M | $162.10M | $165.00M | $227.50M | $181.10M |
| QoQ Change | — | -3.5% | +46.6% | -22.3% | +2.3% | -4.7% | +30.3% | -10.5% | +6.7% | -1.2% | +5.7% | +5.4% | -12.4% | -7.0% | +14.2% | -12.7% | -6.0% | +1.8% | +37.9% | -20.4% |
| YoY Change | — | — | — | — | +12.4% | +11.0% | -1.3% | +13.9% | +18.8% | +23.0% | -0.2% | +17.4% | -3.7% | -9.3% | -2.0% | -18.8% | -12.8% | -4.5% | +15.2% | +5.0% |
Range$139.50M – $227.50M
CAGR+4.9%
Avg YoY Growth+4.0%
Median YoY Growth+2.4%
Accounts Payable at Other Companies
Frequently Asked Questions
- What is Edwards Lifesciences's accounts payable?
- Edwards Lifesciences (EW) reported accounts payable of $181.10M in Q1 2026.
- How has Edwards Lifesciences's accounts payable changed year-over-year?
- Edwards Lifesciences's accounts payable increased by 5.0% year-over-year, from $172.40M to $181.10M.
- What is the long-term trend for Edwards Lifesciences's accounts payable?
- Over 5 years (2020 to 2025), Edwards Lifesciences's accounts payable has grown at a 3.0% compound annual growth rate (CAGR), from $196.50M to $227.50M.
- What does accounts payable mean?
- The total amount of money the company owes to its suppliers for items it has already received.